Top-News

Syndax Pharmaceuticals Aktie News

Aktie
WKN:  A2AFL6 ISIN:  US87164F1057 US-Symbol:  SNDX Branche:  Biotechnologie Land:  USA
16,70 €
-0,2 €
-1,18%
07:30:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,22 Mrd. €
Streubesitz
-
KGV
-3,55
Index-Zuordnung
-

Syndax Pharmaceuticals News

09.02.25 - Boersia.de
Syndax Aktie: Ein neuer Aufbruch!
Die Syndax Pharmaceuticals verzeichnet eine bemerkenswerte Kursentwicklung im laufenden Monat. Der Aktienkurs des Biopharma-​Unternehmens konnte innerhalb der letzten 30 ...
04.02.25 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
30.01.25 - PR Newswire
Syndax Announces Participation in February Investor Conferences
Syndax Announces Participation in February Investor Conferences PR Newswire
15.01.25 - PR Newswire
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-​csfr) 9 mg and 22 mg Vial Sizes PR Newswire
13.01.25 - PR Newswire
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
07.01.25 - PR Newswire
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm PR Newswire
07.01.25 - PR Newswire
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
03.01.25 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
19.12.24 - PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors PR ...
09.12.24 - PR Newswire
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial ...
07.12.24 - PR Newswire
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual ...

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »